StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report released on Monday. The brokerage issued a sell rating on the stock.
Navidea Biopharmaceuticals Trading Down 99.7 %
NAVB opened at $0.00 on Monday. Navidea Biopharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.15. The stock has a market capitalization of $20,016.00, a price-to-earnings ratio of 0.00 and a beta of 0.75. The business has a 50 day moving average of $0.03 and a 200-day moving average of $0.04.
About Navidea Biopharmaceuticals
Recommended Stories
- Five stocks we like better than Navidea Biopharmaceuticals
- What Are Dividend Achievers? An Introduction
- The Top 3 Sectors Poised For Growth This Summer
- Using the MarketBeat Dividend Tax Calculator
- U.S. Steel Stock: Betting on EPS Cut and Merger Uncertainty?
- How Can Investors Benefit From After-Hours Trading
- GitLab Stock: Pioneering the AI-Powered DevSecOps Platform
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.